A brief review of the biochemistry and pharmacology of Eglin c, an elastase inhibitor.

Eglin c is a small protein inhibitor of human leucocyte elastase and cathepsin G which has potential as a therapeutic agent for the treatment of disease states associated with inflammation. In particular, Eglin c has been proven effective in experimental animal models of emphysema and shock. While initial studies indicate that Eglin c is virtually non-toxic and does not produce deleterious effects to the cardiovascular system, central nervous system or basic metabolism (unpublished results), an allergenic potential of the protein has not yet been ruled out.
AuthorsN J Braun, H P Schnebli
JournalEuropean journal of respiratory diseases. Supplement (Eur J Respir Dis Suppl) Vol. 146 Pg. 541-7 ( 1986) ISSN: 0106-4347 [Print] DENMARK
PMID3536558 (Publication Type: Journal Article, Review)
Chemical References
  • Protease Inhibitors
  • Proteins
  • Serpins
  • eglin proteinase inhibitors
  • Animals
  • Chemotaxis (drug effects)
  • Humans
  • Protease Inhibitors (pharmacology)
  • Protein Biosynthesis
  • Proteins (pharmacology, therapeutic use)
  • Pulmonary Emphysema (prevention & control)
  • Serpins
  • Shock, Septic (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: